Sanofi and Regeneron agree new ACC collaboration

Sanofi and Regeneron have announced an innovative new drug research collaboration with the American College of Cardiology (ACC).

The alliance will focus on on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9, which is known to contribute to circulating low-density lipoprotein cholesterol levels.

Under the terms of the agreement, the ACC will apply its expertise in clinical research and use its registries – including the Pinnacle database – to identify patients who might be appropriate candidates for the planned phase III Odyssey Outcomes study.

The collaboration also includes the provision of a comprehensive educational programme to help both physicians and patients to better understand the value of clinical trial research.

Dr Jay Edelberg, vice-president for the PCSK9 development and launch unit at Sanofi, said: "This is the first time that ACC's Pinnacle Registry will be used for clinical trial recruitment and we believe this novel approach will help trial sites meet and hopefully exceed their recruitment goals."

This comes after Sanofi and Regeneron were presented with a research award from Scrip Intelligence for their work on the asthma therapy dupilumab last month.